Table 2 Genomic alterations before and after anti-EGFR therapy in the chemotherapy plus cetuximab subgroups of Group B and Group C.

Patient no.	Sex	Regimens	The duration of therapy (m)/response	Before anti-EGFR				After anti-EGFR
Patient no.	Sex	Regimens	The duration of therapy (m)/response	KRAS	NRAS	BRAF	Site/(S/B/C)	KRAS	NRAS	BRAF	Site/(S/B/C)
B1	M	FOLFOX + C225	1.8/PR	WT	WT	WT	Colon/S	WT	WT	WT	Colon/S
B2	F	XELOX + C225	3.1/PR	WT	WT	WT	Rectum/C	WT	WT	WT	Rectum/S
B3	M	FOLFOX + C225	3.4/PR	WT	WT	WT	Colon/C	WT	WT	WT	Colon/S
B4	F	FOLFOX + C225	3.5/PR	WT	WT	WT	Rectum/C	WT	WT	WT	Rectum/S
B5	F	FOLFOX + C225	4.2/SD	WT	WT	WT	Ovary/S	WT	WT	WT	Colon/S
B6	M	FOLFOX + C225	4.3/PR	WT	WT	WT	Rectum/C	WT	WT	WT	Rectum/S
B7	M	FOLFIRI + C225	5.1/PR	WT	WT	WT	Colon/C	WT	WT	WT	Colon/S
B8	M	XELOX + C225	5.6/SD	WT	WT	WT	Colon/S	WT	WT	WT	Colon/S
B9	M	FOLFIRI + C225	6.8/PR	WT	WT	WT	Colon/S	WT	WT	WT	Colon/S
C1	M	XELODA + C225	1.4/PD	WT	WT	WT	Rectum/S	WT	WT	WT	Rectum/S
C2	F	XELODA + C225	1.9/PD	WT	–	WT	Rectum/S	MT	–	WT	–/–
C3	F	FOLFIRI + C225	3.1/PR	WT	WT	WT	Colon/S	WT	WT	WT	Liver/B
C4	F	FOLFIRI + C225	3.2/PR	WT	WT	WT	Colon/S	WT	WT	WT	Colon/S
C5	M	FOLFOX + C225	5.6/PR	WT	WT	WT	Colon/S	WT	WT	WT	Lymph node/B
C6	M	FOLFOX + C225	6.7/SD	WT	–	–	Colon/C	WT	–	–	Omentum majus/B
C7	M	FOLFIRI + C225	6.8/PR	WT	WT	WT	Colon/S	WT	WT	WT	Bone/S
C8	M	Irinotecan + C225	9.0/SD	WT	WT	WT	Rectum/S	WT	WT	WT	Liver/B
C9	F	FOLFOX + C225	10.3/PR	WT	–	WT	Colon/C	MT	–	WT	Liver/S
C10	M	Irinotecan + C225	11.5/PR	WT	WT	WT	Rectum/S	WT	WT	WT	Liver/B
C11	M	FOLFOX + C225	14.1/PR	WT	WT	WT	Colon/C	WT	WT	WT	Liver/B
C12	F	FOLFIRI + C225	16.8/SD	WT	WT	WT	Rectum/S	WT	WT	WT	Rectum/C
C13	M	CT + C225	23.6/PR	WT	WT	WT	Colon/S	WT	WT	WT	Small intestine/S
C14	M	CT + C225	26.2/SD	WT	WT	WT	Rectum/S	WT	WT	WT	Soft tissue/B
C15	F	CT + C225	41.6/PR	WT	WT	WT	Rectum/C	MT	WT	WT	Liver/B
C16	M	CT + C225	41.9/PR	WT	WT	WT	Rectum/S	WT	WT	MT	Lymph node/B

Group B, first-line chemotherapy without progression group; Group C, first-line chemotherapy with progression group. Secondary genetic mutations are shown in bold. B, Group B; C, Group C; C225, cetuximab; Site/(S/B/C), Site/(surgery/biopsy/colonoscopy); WT, wild type; MT, mutation type; CT, chemotherapy including included FOLFIRI, FOLFOX, or XELOX.

Search